Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its higher-margin oncology assets to lift profitability. Trastuzumab Rezetecan, a HER2-targeted ADC, was in-licensed from China’s Hengrui Pharma in September 2025 for an upfront payment of $18 million and milestone payments of up to $1.093 billion.

Glenmark’s Chairman and MD, Glenn Saldanha, stated that the company’s oncology assets, including Trastuzumab Rezetecan and aumolertinib, will bring meaningful gains from FY28, driving long-term growth for the company. The company has also obtained exclusive rights for select markets, including India, and is exploring the treatment of HER2-positive cancers, such as non-small cell lung cancer (NSCLC) and breast cancer.

In addition to oncology, Glenmark’s leading respiratory asset, Ryaltris, is on track to become a $100 million brand on a moving annual basis. The company is also progressing well with its $1.9 billion out-licensing deal with AbbVie for the cancer asset ISB 2001, with Phase II trials expected to begin by the end of the current calendar year.

Glenmark has a net cash position of around Rs 600 crore and has reiterated its target to reduce gross debt to zero by March 2026. The company’s innovation spin-off, IGI, has an annual cash burn of $70 million. Commenting on the Union Budget 2026-27 announcement of Biopharma SHAKTI, a scheme to boost capacity creation for biologics and biosimilars, Saldanha said it is a positive development for the industry, although Glenmark does not currently have in-house manufacturing for biologics.

Overall, Glenmark is poised for growth driven by its oncology assets, and the company is confident that its strategic decisions will yield meaningful gains from FY28. With a strong focus on innovation and a robust pipeline of products, Glenmark is well-positioned to drive long-term growth and expansion in the pharmaceutical industry. The company’s commitment to reducing debt and increasing profitability is also expected to yield positive results, making it an attractive player in the Indian pharmaceutical sector.

Glenmark Pharmaceuticals has launched an epinephrine injection, which is the first FDA-approved generic version of Auvi-Q, according to a report by Drug Store News. The epinephrine injection, also known as epinephrine injection, USP, is a prescription medication used to treat life-threatening allergic reactions, including anaphylaxis.

The medication is available in a pre-filled syringe and is administered via intramuscular injection, typically in the middle of the outer thigh. It is designed to provide fast and effective relief from severe allergic reactions, which can be caused by a range of allergens, including food, insect stings, and latex.

The launch of the epinephrine injection by Glenmark is significant, as it provides patients with a more affordable alternative to branded products. The list price of Glenmark’s epinephrine injection is expected to be lower than that of Auvi-Q, making it a more accessible option for patients who require this life-saving medication.

Glenmark’s epinephrine injection has been approved by the FDA in two doses: 0.3mg and 0.15mg. The 0.3mg dose is intended for patients who weigh 30kg or more, while the 0.15mg dose is intended for patients who weigh between 15kg and 30kg. The medication is available in a carton of two auto-injectors, each containing a single dose of epinephrine.

The launch of Glenmark’s epinephrine injection is an important development for patients who are at risk of anaphylaxis. Anaphylaxis is a severe and potentially life-threatening allergic reaction that requires immediate medical attention. Symptoms of anaphylaxis can include difficulty breathing, rapid heartbeat, and a drop in blood pressure. If left untreated, anaphylaxis can lead to serious health consequences, including death.

Glenmark’s epinephrine injection provides patients with a reliable and effective treatment option for anaphylaxis. The medication has undergone rigorous testing and has been shown to be safe and effective in clinical trials. With its launch, Glenmark is helping to expand access to this critical medication, making it more widely available to patients who need it.

Overall, the launch of Glenmark’s epinephrine injection is a significant development in the treatment of anaphylaxis. The medication provides patients with a fast and effective treatment option for severe allergic reactions, and its availability is expected to improve health outcomes for patients who are at risk of anaphylaxis.

Glenmark Pharmaceuticals, a leading global pharmaceutical company, has announced the appointment of Neha Jangale as the Head of Learning and Development (L&D). This strategic move aims to further strengthen the company’s commitment to employee development and growth.

Neha Jangale, with her extensive experience in the field of human resources, will be responsible for designing and implementing comprehensive learning and development programs across the organization. Her primary focus will be on creating a culture of continuous learning, enabling employees to acquire new skills, and enhancing their overall performance.

In her new role, Neha will work closely with the leadership team to identify skill gaps and develop targeted training programs to address these gaps. She will also be responsible for creating a robust framework for leadership development, succession planning, and talent management. Her expertise will help in creating a learning ecosystem that supports the company’s business objectives and fosters a culture of innovation and excellence.

Neha’s appointment is a testament to Glenmark’s commitment to investing in its employees and creating a work environment that encourages growth and development. The company recognizes that its employees are its most valuable assets and is dedicated to providing them with the necessary tools and resources to succeed.

Glenmark Pharmaceuticals has a strong track record of developing and implementing innovative L&D programs. The company has a dedicated L&D team that works closely with various stakeholders to design and deliver programs that cater to the diverse needs of its employees. With Neha at the helm, the company is expected to take its L&D initiatives to the next level, focusing on creating a more agile, adaptable, and future-ready workforce.

The appointment of Neha Jangale as the Head of L&D is a significant step forward for Glenmark Pharmaceuticals. Under her leadership, the company is poised to create a learning culture that is aligned with its business strategy and supports the growth and development of its employees. As the pharmaceutical industry continues to evolve, Glenmark is well-positioned to stay ahead of the curve, driven by a talented and skilled workforce. With Neha’s expertise and passion for L&D, the company is expected to achieve its vision of becoming a leading global pharmaceutical company.

The Delhi High Court has issued an interim order restraining Dr. Reddy’s Laboratories from manufacturing and selling its VENUSIA sunscreens with a label that includes the word “SUN”. The court’s decision comes in response to a lawsuit filed by Glenmark Pharmaceuticals, which claims that Dr. Reddy’s is infringing on its trademark rights.

Glenmark Pharmaceuticals had launched its own sunscreen product, SUNSTAR, in 2018, and had obtained a trademark registration for the mark “SUN” in relation to sunscreen products. The company claims that Dr. Reddy’s use of the word “SUN” on its VENUSIA sunscreens is likely to cause confusion among consumers and dilute the distinctiveness of Glenmark’s trademark.

The Delhi High Court has agreed with Glenmark’s arguments, observing that Dr. Reddy’s use of the word “SUN” on its products is likely to cause confusion among consumers, who may mistakenly believe that the VENUSIA sunscreens are connected to Glenmark’s SUNSTAR product. The court has therefore restrained Dr. Reddy’s from using the word “SUN” on its VENUSIA sunscreens, pending the outcome of the lawsuit.

The court’s order is a significant setback for Dr. Reddy’s, which had launched its VENUSIA sunscreens with the SUN label in an attempt to capitalize on the popularity of sunscreens in the Indian market. The company will now have to rebrand its products and remove the SUN label, which could result in significant losses and damage to its reputation.

The lawsuit highlights the importance of trademark protection in the pharmaceutical industry, where companies invest heavily in building their brands and trademarks. The Delhi High Court’s decision demonstrates that courts will take a strict view of trademark infringement, particularly in cases where there is a likelihood of confusion among consumers.

The case will now proceed to trial, where Glenmark will have to prove that Dr. Reddy’s use of the word “SUN” on its VENUSIA sunscreens constitutes trademark infringement. If the court ultimately rules in favor of Glenmark, Dr. Reddy’s could face significant damages and penalties for its alleged infringement. The case is being closely watched by the pharmaceutical industry, which is keen to see how the courts will interpret trademark laws in cases of alleged infringement.

Glenmark Pharmaceuticals Inc, USA, has launched Epinephrine Injection USP, a bioequivalent and therapeutically equivalent product to the reference listed drug manufactured by BPI Labs, LLC. The product is available in a 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial and is intended for the U.S. market. According to IQVIA sales data, the Epinephrine Injection market had annual sales of approximately USD 67.6 million for the 12 months ending October 2025. This launch expands Glenmark’s institutional product portfolio and reinforces its commitment to providing high-quality, affordable treatment options.

Glenmark Pharmaceuticals Limited is a prominent Indian multinational pharmaceutical company that has been in operation since 1977. The company has grown from its origins in generic medicines and active pharmaceutical ingredients (APIs) to become a research-led global healthcare organization with a presence in over 80 countries. Glenmark’s core therapeutic expertise includes respiratory, dermatology, oncology, cardiovascular, and anti-infective treatments, with multiple R&D centres and manufacturing facilities across India and internationally.

In recent years, Glenmark has diversified into innovative drug development and biosimilars, while maintaining a strong portfolio of branded generics in high-growth markets. The company has also entered strategic collaborations and licensing deals to advance novel therapies, particularly in oncology. Despite facing quality control challenges in some manufacturing facilities, Glenmark continues to pursue a transformation towards a more innovation-centric business model aimed at increasing its branded portfolio and long-term global competitiveness.

The launch of Epinephrine Injection USP is part of Glenmark’s strategy to strengthen its institutional channel presence and improve access to essential medicines. According to Marc Kikuchi, President and Business Head for North America at Glenmark, the launch supports the company’s commitment to providing high-quality, affordable treatment options. With its robust revenue growth and expanding demand in key markets such as North America and Europe, Glenmark is well-positioned to continue its growth and expansion in the global pharmaceutical market.